ALB and chronic kidney disease: The recently published DAPA-CKD study included patients with eGFR 25–75 ml/min and albumin/creatinine ratio 200–5,000 mg/g with or without diabetes, and they found that the risk of CKD progression was significantly lower in those treated with dapagliflozin compared to placebo with a median follow-up of 2.4 years (71).